Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint
Ionis Pharmaceuticals (NASDAQ:IONS) shares fell 13. 1% to $50.
Search
Search covers the most recently published. For the full archive, browsethe topics.
1 result for"Xenon Pharmaceuticals"